Aveanna Healthcare (NASDAQ: AVAH – Get Rating) was downgraded by research analysts at Bank of America from a “neutral” rating to an “underperform” rating in a research report issued on Tuesday, The Fly reports. They presently have a $ 2.00 price target on the stock, down from their prior price target of $ 3.00. Bank of America’s target price would suggest a potential downside of 15.61% from the company previous close.
AVAH has been the topic of several other reports. Raymond James lowered their target price on shares of Aveanna Healthcare from $ 12.00 to $ 8.00 and set a “strong-buy” rating on the stock in a research report on Thursday, March 31st. Truist Financial cut their price target on shares of Aveanna Healthcare from $ 10.00 to $ 5.00 and set a “buy” rating for the company in a research note on Wednesday, March 30th. Barclays cut their price target on shares of Aveanna Healthcare from $ 16.00 to $ 7.00 and set an “overweight” rating for the company in a research note on Wednesday, March 30th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Aveanna Healthcare from $ 12.50 to $ 6.00 and set a “buy” rating for the company in a research note on Wednesday, March 30th. Finally, Royal Bank of Canada cut their target price on shares of Aveanna Healthcare from $ 16.00 to $ 9.00 and set an “outperform” rating for the company in a research note on Thursday, March 31st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Aveanna Healthcare has a consensus rating of “Moderate Buy” and an average target price of $ 6.89.
Shares of NASDAQ AVAH opened at $ 2.37 on Tuesday. The stock has a market capitalization of $ 437.81 million, a P / E ratio of -4.56 and a beta of 0.96. The stock’s 50 day moving average price is $ 2.90 and its two-hundred day moving average price is $ 4.60. Aveanna Healthcare has a 52-week low of $ 2.09 and a 52-week high of $ 12.99. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 1.84.
Aveanna Healthcare (NASDAQ: AVAH – Get Rating) last issued its quarterly earnings results on Monday, March 28th. The company reported $ 0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $ 0.11 by ($ 0.01). Aveanna Healthcare had a negative net margin of 5.70% and a positive return on equity of 8.90%. The firm had revenue of $ 414.07 million for the quarter, compared to the estimate consensus of $ 420.19 million. On average, analysts anticipate that Aveanna Healthcare will post 0.35 EPS for the current year.
In related news, CFO David Afshar purchased 12,036 shares of the stock in a transaction that occurred on Monday, May 16th. The stock was acquired at an average price of $ 2.86 per share, with a total value of $ 34,422.96. Following the completion of the acquisition, the chief financial officer now directly owns 272,380 shares in the company, valued at approximately $ 779,006.80. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tony Strange purchased 36,000 shares of the stock in a transaction that occurred on Thursday, May 19th. The stock was bought at an average cost of $ 2.90 per share, with a total value of $ 104,400.00. Following the acquisition, the insider now owns 1,680,134 shares of the company stock, valued at $ 4,872,388.60. The disclosure for this purchase can be found here. In the last three months, insiders purchased 90,136 shares of company stock valued at $ 259,733. 8.60% of the stock is currently owned by company insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Nut Tree Capital Management LP grew its holdings in Aveanna Healthcare by 40.2% during the 4th quarter. Nut Tree Capital Management LP now owns 5,435,479 shares of the company stock worth $ 40,223,000 after acquiring an additional 1,557,591 shares during the period. Vaughan Nelson Investment Management LP grew its holdings in Aveanna Healthcare by 23.5% during the 4th quarter. Vaughan Nelson Investment Management LP now owns 5,354,228 shares of the company stock worth $ 39,621,000 after acquiring an additional 1,018,895 shares during the period. Westwood Holdings Group Inc. grew its holdings in Aveanna Healthcare by 24.9% during the 4th quarter. Westwood Holdings Group Inc. now owns 4,163,789 shares of the company stock worth $ 30,812,000 after acquiring an additional 829,270 shares during the period. BlackRock Inc. grew its holdings in Aveanna Healthcare by 2.3% during the 1st quarter. BlackRock Inc. now owns 3,087,209 shares of the company stock worth $ 10,526,000 after acquiring an additional 69,609 shares during the period. Finally, Principal Financial Group Inc. grew its holdings in Aveanna Healthcare by 5.7% during the 1st quarter. Principal Financial Group Inc. now owns 2,457,839 shares of the company stock worth $ 8,381,000 after acquiring an additional 132,663 shares during the period. 95.00% of the stock is owned by hedge funds and other institutional investors.
Aveanna Healthcare Company Profile: (Get Rating)
Aveanna Healthcare Holdings Inc, a diversified home care platform company, provides private duty nursing (PDN), adult home health and hospice, home-based pediatric therapy, and enteral nutrition services in the United States. Its patient- centered care delivery platform allows patients to remain in their homes and minimizes the overutilization of high-cost care settings, such as hospitals.
Recommended Stories:
Receive News & Ratings for Aveanna Healthcare Daily: – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aveanna Healthcare and related companies with MarketBeat.com’s FREE daily email newsletter.
.